Revision History

1 revisions for "The Pill in the Mailbox: Mifepristone's Future Hinges on an FDA Review with No Guaranteed Outcome"

A federal judge has declined to block mail-order mifepristone but gave the FDA six months to complete a review of the regulations that permit it, placing the drug used in 63% of U.S. abortions on an uncertain trajectory. The ruling affects an estimated 91,000 patients annually in states with total abortion bans who receive the drug by telehealth, while published safety data shows serious adverse event rates below 0.3% for both mail and clinic dispensing.